Literature DB >> 6884410

Metabolism of propranolol in the human maternal-placental-foetal unit.

M T Smith, I Livingstone, M J Eadie, W D Hooper, E J Triggs.   

Abstract

Propranolol (P) and all of its major known metabolites were found in maternal plasma, cord plasma and neonatal plasma in 10 women at term, irrespective of the P doses administered and the time elapsed (up to 15 h) between administration of the last P dose and delivery. The ratios of cord plasma to simultaneous maternal plasma levels for propranolol and its major metabolites (mean +/- SD) were: propranolol 0.32 +/- 0.17, propranolol glucuronide 0.86 +/- 0.36, 4-hydroxypropranolol 1.4 +/- 1.0, 4-hydroxypropranolol glucuronide 0.71 +/- 0.45 and naphthoxylactic acid 3.0 +/- 1.6. P binding in cord plasma at delivery was 67.2 +/- 3.9% (mean +/- SD) which was significantly less ('t' = 13.4, df = 13, p less than 0.001) than the P binding in maternal plasma at delivery (87.5 +/- 1.6%, mean +/- SD). The plasma protein binding (mean +/- SD) of naphthoxylactic acid in cord plasma (98.6 +/- 0.2%) was significantly greater ('t' = 3.808, df = 4, p less than 0.02) than the naphthoxylactic acid binding in maternal plasma at delivery (97.6 +/- 0.4%). When the simultaneous concentrations of P and naphthoxylactic acid in maternal and cord plasma are compared in conjunction with protein binding and ionic effects, it would seem that metabolism of P does occur in the placental/foetal unit.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884410     DOI: 10.1007/bf00607078

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Propranolol therapy during pregnancy, labor, and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition.

Authors:  C M Cottrill; R G McAllister; L Gettes; J A Noonan
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Propranolol therapy during pregnancy and lactation.

Authors:  A A Levitan; J C Manion
Journal:  Am J Cardiol       Date:  1973-08       Impact factor: 2.778

3.  Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites.

Authors:  T Walle; T E Gaffney
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

4.  Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant.

Authors:  M Wood; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

5.  Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.

Authors:  M T Smith; I Livingstone; W D Hooper; M J Eadie; E J Triggs
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

6.  Environmental influences on human foetal and placental xenobiotic metabolism.

Authors:  O Pelkonen
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

Review 7.  Drug metabolism by the human fetus.

Authors:  M R Juchau; S T Chao; C J Omiecinski
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

  7 in total
  4 in total

Review 1.  Migraine during pregnancy: options for therapy.

Authors:  Anthony W Fox; Merle L Diamond; Egilius L H Spierings
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Drug treatment of fetal tachycardias.

Authors:  Martijn A Oudijk; Jopje M Ruskamp; Barbara E Ambachtsheer; Tessa F F Ververs; Philip Stoutenbeek; Gerard H A Visser; Erik J Meijboom
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

4.  Pharmacokinetics of propranolol during pregnancy.

Authors:  M F O'Hare; C D Kinney; G A Murnaghan; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.